Integer Holdings Corporation (ITGR) Stock Price, News & Analysis

Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing organization (CDMO) that works with medical device companies and original equipment manufacturers (OEMs). According to the company’s public disclosures, Integer focuses on serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets, providing products and solutions that support therapies for patients worldwide.

Integer is identified in industry data as operating in surgical and medical instrument manufacturing within the broader manufacturing sector. The company describes itself as a strategic partner to medical device companies and OEMs, emphasizing its role in helping customers bring medical technologies to market. Its brands include Greatbatch Medical and Lake Region Medical, which are referenced in multiple company news releases and SEC filings.

Business focus and product lines

Based on available information, Integer’s business is organized around medical device components and finished devices used in cardiac and vascular care, cardiac rhythm management, and neuromodulation. Earlier descriptions of the company note that it derives revenue from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets. These product lines are also used in the company’s financial reporting, where sales performance is discussed by product line.

The company has also disclosed activity in "Other Markets," which historically has included nonmedical applications. Prior descriptions indicate that Integer develops batteries used in nonmedical applications in the energy, military, and environmental markets. In more recent communications, Integer highlights technologies such as high-performance batteries for implantable devices and integrated implantable pulse generator and lead systems, particularly in the context of neuromodulation and miniaturized active implantable medical devices (AIMDs).

Role as a CDMO in medtech

Integer repeatedly characterizes itself in news releases and SEC filings as one of the largest medical device CDMOs in the world. In this role, it supports customers across the product lifecycle, from contract development through manufacturing. The company emphasizes its ability to provide high-quality products and solutions that are intended to enhance patient lives, and it positions itself as a partner of choice to medical device companies and OEMs.

Within neuromodulation and cardiac rhythm management, Integer highlights expertise across critical components, including high-performance batteries and fully integrated implantable pulse generator and lead systems. The company also presents itself as active in next-generation miniaturized AIMDs, noting that miniaturization is an important trend for implantable technologies and that its technologies are designed to help customers reduce development timelines and risk.

Markets and applications

Integer’s public materials describe its primary markets as:

• Cardio & Vascular – products and technologies used in cardiovascular procedures and therapies, which the company reports as a major product line in its financial results.
• Cardiac Rhythm Management & Neuromodulation – devices and components that support cardiac rhythm therapies and neuromodulation applications, including implantable pulse generators and related systems.
• Other Markets – a product line that has included portable medical and nonmedical applications, as referenced in the company’s financial discussions and prior descriptions of battery technologies for energy, military, and environmental markets.

In its financial press releases, Integer breaks out sales by these product lines and discusses factors such as new product ramps, acquisitions in areas like precision coating and parylene technologies, and customer demand in neurovascular and emerging neuromodulation customers with pre-market approval (PMA) products.

Public company and regulatory context

Integer Holdings Corporation’s common stock trades on the New York Stock Exchange under the ticker symbol ITGR, as confirmed in multiple Form 8-K filings. These filings also show that the company is not classified as an emerging growth company. Integer regularly files current reports on Form 8-K to disclose material events, including quarterly financial results, leadership changes, board appointments, and capital structure updates such as its 2.125% Convertible Senior Notes due 2028 and a share repurchase program authorized by its Board of Directors.

The company reports its financial performance using both GAAP and non-GAAP measures, such as adjusted operating income, adjusted EBITDA, adjusted net income, adjusted earnings per share, and organic sales change. These measures are discussed in detail in its earnings releases, which are furnished as exhibits to Form 8-K filings. Integer also provides outlooks for future periods and supplemental financial information, though those outlooks are forward-looking and subject to risks described in its periodic SEC reports.

Capital allocation and financing

According to a Form 8-K and related press release, Integer’s Board of Directors authorized a share repurchase program of up to a specified dollar amount of its outstanding common stock. The company states that this program may be executed over time, using cash on hand and free cash flows, and that repurchases may occur in the open market, in privately negotiated transactions, or otherwise, at management’s discretion.

In another Form 8-K, Integer disclosed that its 2.125% Convertible Senior Notes due 2028 became convertible at the option of holders for a defined period, based on the trading price of the company’s common stock relative to the conversion price. The filing explains that the notes are convertible into cash up to the principal amount and, at the company’s election, into cash, shares of common stock, or a combination for any amount above principal.

Leadership and governance

Recent Form 8-K filings describe changes in Integer’s leadership and board composition. The Board appointed Payman Khales as President and Chief Executive Officer and as a member of the Board, succeeding the prior CEO, with the former CEO continuing as a special advisor for a transition period. The Employment Agreement for the new CEO, summarized in the Form 8-K, sets out base salary, short-term incentive bonus opportunities, long-term incentive eligibility, special equity grants, and severance arrangements, including provisions related to change in control.

Another Form 8-K details the election of Michael J. Coyle to the Board of Directors and his service on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. The filing notes that his compensation will follow the company’s Director Compensation Policy as described in its annual proxy statement.

Investor communications

Integer regularly issues press releases and hosts conference calls to discuss its quarterly results and business highlights. These calls are typically webcast, and slide presentations with supplemental information are made available. The company also announces participation in healthcare investor conferences and provides webcasts or replays of its presentations.